VALPROATE USE IS ASSOCIATED WITH LOWER HEPATIC AND CARDIOVASCULAR OUTCOMES WHEN COMPARED TO LEVETIRACETAM IN PATIENTS WITH MASLD/MASH: A MULTINATIONALANALYSIS

Authors

Donghyun Ko, Department of Internal Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT, USA.Follow
Do Han Kim MD, Department of Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Wilhelm S. Basegoda MD, University of South Alabama, Mobile, AL, USA
Jose A. Porres, Universidad Francisco Marroquin, Guatemala City, Guatemala.
Luis M. Nieto MD, Division of Gastroenterology and Hepatology, Emory University, Atlanta, GA, USA.
Pedro Palacios Argueta MD, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA, USA
Paul T. Kroner MD, Department of Gastroenterology, Riverside Health System, Newport News, VA, USA.
Frank J. Lukens MD, Division of Gastroenterology and Hepatology, Mayo Clinic Florida, Jacksonville, FL, USA

Document Type

Conference Proceeding

Abstract

Valproate and levetiracetam are commonly used to manage epilepsy. While valproate is well-documented to significantly affect lipid metabolism, less is known about the effects of levetiracetam. Given this, worse outcomes in MASLD/MASH are anticipated in patients treated with valproate.

The aim of our study is to compare hepatic and cardiovascular outcomes in MASLD/MASH patients treated with valproate versus levetiracetam.

Publication Date

5-2025

Recommended Citation

Ko, Donghyun; Kim, Do Han MD; Basegoda, Wilhelm S. MD; Porres, Jose A.; Nieto, Luis M. MD; Palacios Argueta, Pedro MD; Kroner, Paul T. MD; and Lukens, Frank J. MD, "VALPROATE USE IS ASSOCIATED WITH LOWER HEPATIC AND CARDIOVASCULAR OUTCOMES WHEN COMPARED TO LEVETIRACETAM IN PATIENTS WITH MASLD/MASH: A MULTINATIONALANALYSIS" (2025). Posters. 106.
https://scholar.bridgeporthospital.org/poster_presentations/106